Acumen Historical Balance Sheet

ABOS Stock

USD 1.17 0.06 4.88%

Trend analysis of Acumen Pharmaceuticals balance sheet accounts such as Other Current Liab of 5.9 M, Total Current Liabilities of 15.7 M or Total Stockholder Equity of 322.4 M provides information on Acumen Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Acumen Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Acumen Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Acumen Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Acumen Pharmaceuticals is a good buy for the upcoming year.

Acumen Pharmaceuticals Inventory

118,335

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.

About Acumen Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Acumen Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Acumen Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Acumen Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Acumen currently owns. An asset can also be divided into two categories, current and non-current.

Acumen Pharmaceuticals Balance Sheet Chart

At this time, Acumen Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Inventory is likely to gain to about 118.3 K in 2025, whereas Net Debt is likely to drop (36.3 M) in 2025.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable Short Long Term Debt Total

Total Assets

Total assets refers to the total amount of Acumen Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Acumen Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Acumen Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Acumen Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Acumen Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Acumen Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Acumen Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Acumen Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acumen Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.At this time, Acumen Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Inventory is likely to gain to about 118.3 K in 2025, whereas Net Debt is likely to drop (36.3 M) in 2025.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	6.0M	9.9M	11.3M	5.9M
Total Assets	196.6M	310.1M	356.6M	374.5M

Other Current Liab Total Assets

Acumen Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Long Term Debt Total	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.88	0.96	0.99	0.96	-0.55	-0.97	0.91	0.81	0.97	0.77	-0.88	0.94	0.79	0.8	-0.01	0.46	0.88	1.0	0.2	1.0	0.94	0.94	0.87	-0.7	-0.82
Other Current Liab	0.88		0.92	0.85	0.8	-0.48	-0.89	0.9	0.71	0.85	0.68	-0.9	0.93	0.8	0.86	0.34	0.55	0.74	0.89	0.55	0.85	0.92	0.92	0.8	-0.46	-0.79
Total Current Liabilities	0.96	0.92		0.92	0.86	-0.42	-0.93	0.86	0.71	0.95	0.82	-0.89	0.88	0.9	0.84	0.23	0.64	0.73	0.96	0.42	0.94	0.88	0.87	0.92	-0.74	-0.84
Total Stockholder Equity	0.99	0.85	0.92		0.98	-0.6	-0.98	0.92	0.84	0.96	0.74	-0.86	0.95	0.73	0.77	-0.11	0.37	0.91	0.99	0.1	1.0	0.95	0.95	0.83	-0.67	-0.82
Net Tangible Assets	0.96	0.8	0.86	0.98		-0.72	-0.96	0.94	0.91	0.89	0.62	-0.87	0.94	0.6	0.67	-0.21	0.2	0.96	0.97	0.0	0.97	0.95	0.95	0.72	-0.58	-0.79
Net Debt	-0.55	-0.48	-0.42	-0.6	-0.72		0.61	-0.75	-0.93	-0.35	0.06	0.75	-0.66	0.0	-0.1	0.29	0.38	-0.79	-0.59	0.16	-0.56	-0.66	-0.67	-0.08	0.06	0.5
Retained Earnings	-0.97	-0.89	-0.93	-0.98	-0.96	0.61		-0.96	-0.83	-0.93	-0.74	0.88	-0.96	-0.72	-0.77	0.06	-0.36	-0.88	-0.98	-0.17	-0.98	-0.96	-0.96	-0.82	0.57	0.91
Accounts Payable	0.91	0.9	0.86	0.92	0.94	-0.75	-0.96		0.92	0.81	0.57	-0.92	0.97	0.58	0.7	-0.06	0.2	0.89	0.93	0.17	0.91	0.97	0.97	0.67	-0.43	-0.87
Cash	0.81	0.71	0.71	0.84	0.91	-0.93	-0.83	0.92		0.65	0.29	-0.9	0.86	0.34	0.41	-0.19	-0.06	0.92	0.84	-0.02	0.81	0.86	0.86	0.43	-0.36	-0.71
Non Current Assets Total	0.97	0.85	0.95	0.96	0.89	-0.35	-0.93	0.81	0.65		0.87	-0.78	0.88	0.89	0.87	0.06	0.61	0.78	0.96	0.26	0.97	0.88	0.88	0.95	-0.76	-0.77
Non Currrent Assets Other	0.77	0.68	0.82	0.74	0.62	0.06	-0.74	0.57	0.29	0.87		-0.48	0.62	0.9	0.87	0.09	0.75	0.43	0.75	0.26	0.77	0.62	0.62	0.96	-0.78	-0.73
Other Assets	-0.88	-0.9	-0.89	-0.86	-0.87	0.75	0.88	-0.92	-0.9	-0.78	-0.48		-0.89	-0.64	-0.61	-0.21	-0.33	-0.83	-0.9	-0.39	-0.86	-0.89	-0.89	-0.65	0.48	0.76
Cash And Short Term Investments	0.94	0.93	0.88	0.95	0.94	-0.66	-0.96	0.97	0.86	0.88	0.62	-0.89		0.65	0.8	-0.01	0.29	0.93	0.95	0.22	0.94	1.0	1.0	0.74	-0.44	-0.8
Net Receivables	0.79	0.8	0.9	0.73	0.6	0.0	-0.72	0.58	0.34	0.89	0.9	-0.64	0.65		0.87	0.44	0.9	0.44	0.77	0.59	0.76	0.65	0.64	0.97	-0.78	-0.65
Common Stock Shares Outstanding	0.8	0.86	0.84	0.77	0.67	-0.1	-0.77	0.7	0.41	0.87	0.87	-0.61	0.8	0.87		0.24	0.7	0.59	0.79	0.43	0.79	0.79	0.79	0.91	-0.61	-0.64
Non Current Liabilities Total	-0.01	0.34	0.23	-0.11	-0.21	0.29	0.06	-0.06	-0.19	0.06	0.09	-0.21	-0.01	0.44	0.24		0.68	-0.24	-0.02	0.97	-0.08	-0.01	-0.02	0.21	-0.04	0.05
Inventory	0.46	0.55	0.64	0.37	0.2	0.38	-0.36	0.2	-0.06	0.61	0.75	-0.33	0.29	0.9	0.7	0.68		0.03	0.43	0.74	0.41	0.29	0.28	0.79	-0.65	-0.34
Other Current Assets	0.88	0.74	0.73	0.91	0.96	-0.79	-0.88	0.89	0.92	0.78	0.43	-0.83	0.93	0.44	0.59	-0.24	0.03		0.88	-0.05	0.89	0.93	0.94	0.57	-0.38	-0.64
Other Stockholder Equity	1.0	0.89	0.96	0.99	0.97	-0.59	-0.98	0.93	0.84	0.96	0.75	-0.9	0.95	0.77	0.79	-0.02	0.43	0.88		0.19	0.99	0.95	0.95	0.85	-0.68	-0.85
Total Liab	0.2	0.55	0.42	0.1	0.0	0.16	-0.17	0.17	-0.02	0.26	0.26	-0.39	0.22	0.59	0.43	0.97	0.74	-0.05	0.19		0.13	0.21	0.2	0.39	-0.12	-0.17
Net Invested Capital	1.0	0.85	0.94	1.0	0.97	-0.56	-0.98	0.91	0.81	0.97	0.77	-0.86	0.94	0.76	0.79	-0.08	0.41	0.89	0.99	0.13		0.94	0.94	0.86	-0.69	-0.83
Total Current Assets	0.94	0.92	0.88	0.95	0.95	-0.66	-0.96	0.97	0.86	0.88	0.62	-0.89	1.0	0.65	0.79	-0.01	0.29	0.93	0.95	0.21	0.94		1.0	0.74	-0.44	-0.8
Net Working Capital	0.94	0.92	0.87	0.95	0.95	-0.67	-0.96	0.97	0.86	0.88	0.62	-0.89	1.0	0.64	0.79	-0.02	0.28	0.94	0.95	0.2	0.94	1.0		0.73	-0.44	-0.79
Short Long Term Debt Total	0.87	0.8	0.92	0.83	0.72	-0.08	-0.82	0.67	0.43	0.95	0.96	-0.65	0.74	0.97	0.91	0.21	0.79	0.57	0.85	0.39	0.86	0.74	0.73		-0.79	-0.73
Common Stock Total Equity	-0.7	-0.46	-0.74	-0.67	-0.58	0.06	0.57	-0.43	-0.36	-0.76	-0.78	0.48	-0.44	-0.78	-0.61	-0.04	-0.65	-0.38	-0.68	-0.12	-0.69	-0.44	-0.44	-0.79		0.48
Retained Earnings Total Equity	-0.82	-0.79	-0.84	-0.82	-0.79	0.5	0.91	-0.87	-0.71	-0.77	-0.73	0.76	-0.8	-0.65	-0.64	0.05	-0.34	-0.64	-0.85	-0.17	-0.83	-0.8	-0.79	-0.73	0.48

Click cells to compare fundamentals

Acumen Pharmaceuticals Account Relationship Matchups

Acumen Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	44.4M	230.3M	196.6M	310.1M	356.6M	374.5M
Other Current Liab	5.8M	4.1M	6.0M	9.9M	11.3M	5.9M
Total Current Liabilities	6.4M	5.1M	7.8M	13.0M	14.9M	15.7M
Total Stockholder Equity	(18.6M)	225.2M	188.8M	267.0M	307.0M	322.4M
Net Debt	(43.8M)	(122.2M)	(130.0M)	(38.4M)	(34.6M)	(36.3M)
Retained Earnings	(27.0M)	(127.6M)	(170.4M)	(222.8M)	(200.5M)	(190.5M)
Accounts Payable	531K	1.1M	1.6M	1.4M	1.6M	1.1M
Cash	43.8M	122.2M	130.1M	66.9M	76.9M	81.3M
Non Current Assets Total	0.0	31.7M	16.3M	63.5M	73.0M	76.7M
Cash And Short Term Investments	43.8M	194.2M	177.6M	243.5M	280.1M	146.5M
Net Receivables	109K	(83.0)	(199.0)	225K	258.8K	271.7K
Liabilities And Stockholders Equity	44.4M	230.3M	196.6M	310.1M	356.6M	374.5M
Non Current Liabilities Total	56.7M	4.1M	1.7M	30.2M	27.2M	17.6M
Inventory	91K	83.0	199.0	98K	112.7K	118.3K
Other Current Assets	543K	4.4M	2.7M	2.9M	3.3M	2.4M
Other Stockholder Equity	65.0M	353.0M	359.9M	489.5M	562.9M	591.0M
Total Liab	63.0M	5.1M	7.8M	43.2M	38.8M	22.1M
Net Invested Capital	(18.6M)	225.2M	188.8M	294.3M	338.5M	355.4M
Total Current Assets	44.4M	198.7M	180.3M	246.6M	283.6M	149.0M
Net Working Capital	38.1M	193.5M	172.5M	233.6M	268.7M	141.6M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Acumen Stock Analysis

When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Acumen Historical Balance Sheet

Acumen Pharmaceuticals Inventory

118,335

About Acumen Balance Sheet Analysis

Acumen Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Acumen Pharmaceuticals balance sheet Correlations

Acumen Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Acumen Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Acumen Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Total Current Assets

Net Invested Capital	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.97	Total Assets
Net Working Capital	- 0.96	Retained Earnings
Total Current Assets	- 0.96	Retained Earnings